List view / Grid view

Subin Baral (EY Global)

 

article

Shifting from megamergers to strategic collaboration: M&A predictions for biopharma

In 2021 we saw deals move away from the massive…

30 March 2022 | By

In 2021 we saw deals move away from the massive megamergers of 2019 to smaller collaboration and partnership agreements. In this article, European Pharmaceutical Review’s Hannah Balfour discusses the key deals of last year, whether the trend of high volume but small value will continue in 2022, and the motivations…